dismiss

Get a Free 3-Day Pass to AAMI 2014 in Philadelphia, May 31-June 2 -- Visit DOTmed, Booth 231

SEARCH

Current Location: DOTmed News > Industry Headlines > This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

More Industry Headlines

FDA clears new CT system from Siemens Ideal for challenging cases.

FDA OKs Shimadzu's new R/F system For a wide variety of exams.

Gov. Jan Brewer signs breast density law Arizona becomes the latest state with inform legislation.

CT can detect arterial plaque for diabetics CCTA is a welcome development.

Goggles that illuminate cancer cells Could they reduce second surgeries?

Philips suspends CT and PET/CT production at Ohio facility Setback for customers and the company.

Varian's seven year patent dispute comes to an end Company will pay about $35 million.

FDA OKs GE's new CT scanner Ideal for challenging cases.

MRI technique can help treat concussion patients Measures white brain matter damage.

What's the big-picture impact of HIT on health care? Q&A with thought leader Bipin Thomas.

Varian backs radiosurgery vs. traditional surgery study

by Brendon Nafziger , DOTmed News Associate Editor
Varian Medical Systems said last week it's contributing funds to help with patient accrual efforts for a National Cancer Institute-sponsored, multi-center study comparing radiosurgery against the knife-based kind for high-risk patients with early-stage lung cancer.

A Varian spokeswoman told DOTmed News the Sunnyvale, Calif-based company will kick in some funds and provide other help to support the study's goal of accruing 420 patients over a five-year period. As of June, 45 centers had qualified to participate in the phase III trial, the company said.

Story Continues Below Advertisement

Introducing the Radimetrics Enterprise Platform

Merge & mobilize patient dose histories and current exam details across the organization. Because Each Dose Matters.Visit us at SIIM, Booth #217



The NCI-financed project is being run by the Alliance for Clinical Trials in Oncology, a one-year-old collaboration among three cancer research organizations: the American College of Surgeons Oncology Group, Cancer and Leukemia Group B and North Central Cancer Treatment Group.

Formally known as ACOSOG Z4099/RTOG 1021, the study seeks to compare whole-body stereotactic radiosurgery, which uses higher doses of radiation in fewer fractions, against sublobar resection, the surgical removal of part of the lobe of the lung, for high-risk patients with non-small cell lung cancer whose cancer is operable.

"To date, there have not been any prospective, randomized trials to compare the efficacy and toxicity of surgery to radiosurgery for high-risk operable early-stage lung cancer patients," Kolleen Kennedy, president of Varian's oncology systems business, said in a statement. "We anticipate that this trial could yield very useful information for making treatment decisions about these types of cases."

According to a "talking points" document hosted on ACOSOG's website, an earlier study involving radiosurgery performed on patients with medically inoperable early-stage lung cancer achieved 56 percent survival rates after three years, double the reported rates for conventional radiation therapy. The researchers are hoping for higher survival rates in the high-risk operable population involved in the current study.

Varian makes the TrueBeam STx and the Trilogy Tx radiosurgery devices.

Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED